This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bayer (BAYRY) Elinzanetant Meets Goals in Late-Stage Studies
by Zacks Equity Research
Bayer's (BAYRY) experimental candidate, elinzanetant, for the non-hormonal treatment of moderate to severe vasomotor symptoms, meets primary and secondary goals in phase III studies.
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
by Zacks Equity Research
Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
by Zacks Equity Research
Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.
HRMY or ACAD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRMY vs. ACAD: Which Stock Is the Better Value Option?
Ultragenyx (RARE) Posts Update From AS Study of GTX-102
by Zacks Equity Research
Ultragenyx (RARE) completes enrollment in the phase I/II study of GTX-102 for the treatment of pediatric patients with AS. Top-line data from the study is expected in the first half of 2024.
Anavex (AVXL) Falls 35% on Mixed Rett Syndrome Study Results
by Zacks Equity Research
Anavex (AVXL) falls 35% on mixed results from the mid to late-stage study of 30 mg ANAVEX2-73 for the treatment of pediatric Rett Syndrome patients aged 5-17 years.
Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.
Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News
by Zacks Equity Research
bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.
Acadia (ACAD) Rises 35% on Positive Patent Ruling for Nuplazid
by Zacks Equity Research
Acadia (ACAD) announces a ruling from the U.S. District Court in Delaware, strongly in favor of the company for its patent for Nuplazid. The stock surges 35% in response.
Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how GSK (GSK) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
Acadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWS
by Zacks Equity Research
Acadia (ACAD) begins late-stage development of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome.
bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How
by Zacks Equity Research
bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its approved therapies.
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)
by Zacks Equity Research
Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.
Avidity (RNA) Expands Collaboration With BMY, Shares Rise
by Zacks Equity Research
Avidity (RNA) gains on the expansion of its existing partnership with BMY to discover multiple cardiovascular targets.
Tharimmune (THAR) Up on Positive Data From Pipeline Candidate
by Zacks Equity Research
Tharimmune (THAR) announces positive data from a phase I study on TH104 and the development timeline in chronic pruritis in primary biliary cholangitis indication.
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study
by Zacks Equity Research
Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
by Zacks Equity Research
Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.
Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan
by Zacks Equity Research
Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.
Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why
by Zacks Equity Research
Atara's (ATRA) shares fell after a phase II study evaluating its multiple sclerosis therapy did not meet its primary endpoint.
Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals
by Zacks Equity Research
Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.
MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study
by Zacks Equity Research
Though data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint.
Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock
by Zacks Equity Research
Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.
Avita (RCEL) Falls 19% on Lowered 2023 Revenue Guidance
by Zacks Equity Research
Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.
5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.
Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson
by Zacks Equity Research
Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.